249 related articles for article (PubMed ID: 22896685)
61. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
62. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
63. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
[TBL] [Abstract][Full Text] [Related]
64. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
65. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
[TBL] [Abstract][Full Text] [Related]
66. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
67. The changing view of high-grade serous ovarian cancer.
Berns EM; Bowtell DD
Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
69. Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
Xu J; Lu W; Wei X; Zhang B; Yang H; Tu M; Chen X; Wu S; Guo T
Cancer Lett; 2024 Jul; 593():216928. PubMed ID: 38714290
[TBL] [Abstract][Full Text] [Related]
70. Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma.
Maeda O; Kajiyama H; Shibata K; Nakamura S; Kikkawa F
Anticancer Res; 2020 May; 40(5):2497-2507. PubMed ID: 32366394
[TBL] [Abstract][Full Text] [Related]
71. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
72. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Arend RC; Londoño AI; Montgomery AM; Smith HJ; Dobbin ZC; Katre AA; Martinez A; Yang ES; Alvarez RD; Huh WK; Bevis KS; Straughn JM; Estes JM; Novak L; Crossman DK; Cooper SJ; Landen CN; Leath CA
Mol Cancer Res; 2018 May; 16(5):813-824. PubMed ID: 29523763
[TBL] [Abstract][Full Text] [Related]
73. Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry.
van der Ploeg P; van Lieshout LAM; van de Stolpe A; Bosch SL; Lentjes-Beer MHFM; Bekkers RLM; Piek JMJ
Cell Oncol (Dordr); 2021 Aug; 44(4):951-957. PubMed ID: 33723801
[TBL] [Abstract][Full Text] [Related]
74. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
[TBL] [Abstract][Full Text] [Related]
75. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
76. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
77. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
78. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
79. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
[TBL] [Abstract][Full Text] [Related]
80. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
